A Phase 2 interventional study of avatrombopag in Severe Aplastic Anemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Status unknown at 1 site in China. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-02-09.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.
Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 7th largest by planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2022, is one of 14 in phase 2, and was the 11th registered.
373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.
Browse Anemia, Aplastic studies →16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–40
By country, each count listing its studies:
Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.
This study: 12 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 17
First in 2012; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 53 is above the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 40 across the 25 interventional studies, 462 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
3 of the studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06254560Institute of Hematology & Blood Diseases Hospital, ChinaRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | 2026-12-30 |
| NCT07297550Institute of Hematology & Blood Diseases Hospital, ChinaSafety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia | 2026-12-31 |
| NCT06936930Institute of Hematology & Blood Diseases Hospital, ChinaReproductive and Mental Health of Patients With Aplastic Anemia | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center study aims to evaluate the early efficacy and safety of avatrombopag combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic anemia (SAA).
This is a single center, single arm, phase II clinical study. Fifty-three patients will be enrolled.
Treatment protocol is as follows: 1) Anti-human thymocyte porcine immunoglobulin (P-ATG 20mg/kg/d) or rabbit anti human thymocyte globulin (R-ATG 3.0mg/kg/d) was administered intravenously for 5 days; 2) Cyclosporine (CSA) is given at 3-5 mg/kg.d in divided doses for at least 6 months. The trough concentration is maintained at 150-250 ng/ml. 3) Avatrombopag is given orally at 60 mg once a day for patients with body weight ≥ 50 kg, and 40 mg orally once a day for patients with body weight\<50 kg, for a total of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
53 subjects will be enrolled with the indicated treatment dose of avatrombopag.
Drug: avatrombopag
Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.
Also known as: AVA, APAG
Treatment response
Percentage of patients who achieves complete response(CR) at 12 weeks.
Time frame: From the start of study treatment (Day1) to end of week 12.
Treatment response
Percentage of patients achieving hematologic response (OR) at 12 weeks.
Time frame: From the start of study treatment (Day1) to end of week 12.
Treatment response
Percentage of patients achieving hematologic response and complete response (OR and CR) at 24 weeks.
Time frame: From the start of study treatment (Day1) to end of week 24.
Supportive treatment
The time of red blood cell or platelet recovery to transfusion independence.
Time frame: From the start study treatment (Day1) up to transfusion independence.
Incidence of Treatment-Emergent Adverse Events by CTCAE
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: From the start study treatment (Day1) up to week 12.
Dose-effect relationship
Correlation between avatrombopag's serum concentration with total and complete hematological response rate.
Time frame: From the start study treatment(Day1) up to week 24.
Change of CD34+ cell
Change of CD34+ cells' proportion in bone marrow before and after avatrombopag treatment at week 12 and 24.
Time frame: From the start study treatment(Day1) up to end of week 12 and 24.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Nov 2023, 12 months after the start.
Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 12 months is below that.
Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag
Institute of Hematology & Blood Diseases Hospital, China →